The shares of the Pharmaceuticals company, specializing in developing and manufacturing critical care injectable pharmaceuticals, jumped upto 13 percent after receiving US FDA approval for Qualified Infectious Disease Product (QIDP) designation for its novel drug formulation VRP-034.
Price action
With a market capitalization of Rs. 161.10 Crores on Thursday, the shares of Venus Remedies Limited jumped upto 13.6 percent, making a high of Rs. 354.00 compared to its previous closing price of Rs. 311.60.
What Happened
Venus Remedies specializes in developing and manufacturing critical care injectable pharmaceuticals, has received the US FDA’s approval for Qualified Infectious Disease Product (QIDP) designation for its novel drug formulation VRP-034, a next-generation polymyxin B sulphate designed to treat bloodstream infections while significantly reducing kidney toxicity.
Key preclinical findings for VRP-034 include:
- Up to 70 percent reduction in nephrotoxicity compared to the marketed PMB
- Robust efficacy against resistant pathogens in both in vitro and animal models
- Favorable safety profiles across multiple toxicity studies using advanced rental biomarkers and human organ-on-a-chip models
About the Company
Venus Remedies Limited is a research-driven pharmaceutical company headquartered in Panchkula, India. Established in 1989, it specializes in manufacturing super-specialty injectable formulations in critical care segments such as oncology, anti-infectives, neurology, and pain management. The company operates in over 80 countries, with exports contributing to more than 70 percent of its revenue.
Key Insights
The company’s P/E ratio of 14.94 is well below the industry average of 53.03, suggesting it may be undervalued. It has a low debt-to-equity ratio of 0.08, indicating strong financial health.
Financials
The company’s revenue rose by 22.7 percent from Rs. 145.77 crore to Rs. 178.89 crore in Q3FY24-25. Meanwhile, Net profit rose from Rs. 6.85 crores to Rs. 19.6 crores during the same period.
Written by Sridhar J
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
